AR057197A1 - Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona - Google Patents
Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanonaInfo
- Publication number
- AR057197A1 AR057197A1 ARP060105249A ARP060105249A AR057197A1 AR 057197 A1 AR057197 A1 AR 057197A1 AR P060105249 A ARP060105249 A AR P060105249A AR P060105249 A ARP060105249 A AR P060105249A AR 057197 A1 AR057197 A1 AR 057197A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halogen
- halogenoalkyl
- cyano
- substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- 102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
- 108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos son utiles para el tratamiento y/o prevencion de enfermedades asociadas con la modulacion de receptores de la H3, Antidiabético. Reivindicacion 1: Compuestos de la formula general (1) en la que R1 se elige entre el grupo formado por H, alquilo inferior, hidroxialquilo inferior, alcoxialquilo inferior, halogenoalquilo inferior, cicloalquilalquilo inferior, alcanoílo inferior, alcoxicarbonilo inferior, cianoalquilo inferior, alquilsulfonilo inferior, fenilsulfonilo, cuyo anillo fenilo puede estar sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, ciano, halogenoalquilo inferior, alcoxi inferior, halogenoalcoxi inferior e hidroxialquilo inferior; fenilo sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, ciano, halogenoalquilo inferior, alcoxi inferior, halogenoalcoxi inferior e hidroxialquilo inferior; fenilalquilo inferior, cuyo anillo fenilo puede estar sin sustituir o sustituido por uno o dos grupos elegidos con independencia entre sí entre alquilo inferior, halogeno, ciano, halogenoalquilo inferior, alcoxi inferior, halogenoalcoxi inferior e hidroxialquilo inferior; y heteroarilo sin sustituir o sustituido por uno o dos grupos elegido con independencia entre sí entre alquilo inferior, alcoxi inferior, halogeno, halogenoalquilo inferior, halogenoalcoxi inferior y ciano; R2 es H o halogeno; G es un resto elegido entre los restos (G1) a (G4) en los que m es el numero 0, 1 o 2; R3 se elige entre alquilo inferior, halogenoalquilo inferior, cicloalquilo, halogenocicloalquilo, cicloalquilalquilo inferior y fenilalquilo inferior; n es el numero 0, 1 o 2; R4 es alquilo inferior; p es el numero 0, 1 o 2; q es el numero 0, 1 o 2; A se elige entre CR10R10', O y S; R5, R5', R6, R6', R7, R7', R10 y R10' con independencia entre sí se eligen entre el grupo formado por H, alquilo inferior, hidroxi, halogeno y dialquilamino, o R6 y R10 forman, juntos, un doble enlace; R8 es alquilo inferior; R9 es alquilo C3-6; y las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111479 | 2005-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057197A1 true AR057197A1 (es) | 2007-11-21 |
Family
ID=37715997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105249A AR057197A1 (es) | 2005-11-30 | 2006-11-28 | Derivados de 1, 1-dioxo-tiomorfolinil-indolil-metanona |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7538101B2 (es) |
| EP (1) | EP1968967B1 (es) |
| JP (1) | JP4879996B2 (es) |
| KR (1) | KR101047204B1 (es) |
| CN (1) | CN101316838B (es) |
| AR (1) | AR057197A1 (es) |
| AT (1) | ATE507222T1 (es) |
| AU (1) | AU2006319232B2 (es) |
| BR (1) | BRPI0619266A2 (es) |
| CA (1) | CA2630307A1 (es) |
| DE (1) | DE602006021626D1 (es) |
| ES (1) | ES2362929T3 (es) |
| NO (1) | NO20082214L (es) |
| RU (1) | RU2412182C2 (es) |
| TW (1) | TWI327144B (es) |
| WO (1) | WO2007062997A1 (es) |
| ZA (1) | ZA200804349B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0619268A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
| CA2630270A1 (en) * | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | 5-substituted indole-2-carboxamide derivatives |
| ES2627221T3 (es) * | 2006-12-28 | 2017-07-27 | Rigel Pharmaceuticals, Inc. | Compuestos de heterocicloalquiloxibenzamida N-sustituidos y métodos de uso |
| WO2009013195A1 (en) * | 2007-07-25 | 2009-01-29 | F. Hoffmann-La Roche Ag | Benzofuran- and benzo[b]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
| MX382569B (es) | 2007-11-16 | 2025-03-13 | Rigel Pharmaceuticals Inc | Compuesto de carboxamida, sulfonamida y amina para trastornos metabolicos. |
| WO2009076631A1 (en) | 2007-12-12 | 2009-06-18 | Rigel Pharmaceuticals, Inc. | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| CN102099357B (zh) | 2008-04-23 | 2014-07-02 | 里格尔药品股份有限公司 | 用于治疗代谢障碍的甲酰胺化合物 |
| US8785435B2 (en) * | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
| HRP20161167T1 (hr) * | 2012-08-23 | 2016-11-04 | Suven Life Sciences Limited | Spoj akrilamida kao ligandi histaminskog h3 receptora |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| US5246960A (en) * | 1984-12-21 | 1993-09-21 | Hoffmann-La Roche Inc. | Oxetanones |
| CA1270837A (en) * | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5338755A (en) * | 1990-07-31 | 1994-08-16 | Elf Sanofi | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| HU227568B1 (en) * | 1997-12-24 | 2011-08-29 | Sanofi Aventis Deutschland | Indole derivatives, as inhibitors os factor xa |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| EP0978512A1 (en) * | 1998-07-29 | 2000-02-09 | Societe Civile Bioprojet | Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications |
| KR20010079636A (ko) | 1998-08-14 | 2001-08-22 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물 |
| KR20010079635A (ko) | 1998-08-14 | 2001-08-22 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 리파아제 저해제를 함유하는 약학 조성물 |
| TR200102805T2 (tr) | 1999-03-29 | 2002-04-22 | F.Hoffmann-La Roche Ag | Glikokinaz aktivatörleri |
| WO2002072548A2 (en) * | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
| GB0224084D0 (en) * | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| AU2003274053A1 (en) * | 2002-10-22 | 2004-05-13 | Glaxo Group Limited | Aryloxyalkylamine derivates as h3 receptor ligands |
| PL1761519T3 (pl) * | 2004-06-21 | 2008-09-30 | Hoffmann La Roche | Pochodne indolu jako antagoniści receptorów histaminowych |
| BRPI0619268A2 (pt) * | 2005-11-30 | 2011-09-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal |
-
2006
- 2006-11-20 RU RU2008126389/04A patent/RU2412182C2/ru not_active IP Right Cessation
- 2006-11-20 EP EP06830045A patent/EP1968967B1/en not_active Not-in-force
- 2006-11-20 JP JP2008542714A patent/JP4879996B2/ja not_active Expired - Fee Related
- 2006-11-20 KR KR1020087015759A patent/KR101047204B1/ko not_active Expired - Fee Related
- 2006-11-20 CA CA002630307A patent/CA2630307A1/en not_active Abandoned
- 2006-11-20 WO PCT/EP2006/068649 patent/WO2007062997A1/en not_active Ceased
- 2006-11-20 BR BRPI0619266-1A patent/BRPI0619266A2/pt not_active IP Right Cessation
- 2006-11-20 AT AT06830045T patent/ATE507222T1/de active
- 2006-11-20 AU AU2006319232A patent/AU2006319232B2/en not_active Ceased
- 2006-11-20 ES ES06830045T patent/ES2362929T3/es active Active
- 2006-11-20 CN CN2006800448115A patent/CN101316838B/zh not_active Expired - Fee Related
- 2006-11-20 DE DE602006021626T patent/DE602006021626D1/de active Active
- 2006-11-28 AR ARP060105249A patent/AR057197A1/es not_active Application Discontinuation
- 2006-11-28 US US11/605,005 patent/US7538101B2/en not_active Expired - Fee Related
- 2006-11-28 TW TW095143983A patent/TWI327144B/zh active
-
2008
- 2008-05-14 NO NO20082214A patent/NO20082214L/no not_active Application Discontinuation
- 2008-05-20 ZA ZA200804349A patent/ZA200804349B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804339A (en) | 2008-01-16 |
| TWI327144B (en) | 2010-07-11 |
| RU2008126389A (ru) | 2010-01-10 |
| KR101047204B1 (ko) | 2011-07-06 |
| CN101316838B (zh) | 2013-01-30 |
| JP4879996B2 (ja) | 2012-02-22 |
| AU2006319232B2 (en) | 2012-09-13 |
| KR20080076979A (ko) | 2008-08-20 |
| EP1968967B1 (en) | 2011-04-27 |
| ZA200804349B (en) | 2009-04-29 |
| DE602006021626D1 (de) | 2011-06-09 |
| NO20082214L (no) | 2008-07-31 |
| US20070123526A1 (en) | 2007-05-31 |
| BRPI0619266A2 (pt) | 2011-09-27 |
| CA2630307A1 (en) | 2007-06-07 |
| AU2006319232A1 (en) | 2007-06-07 |
| RU2412182C2 (ru) | 2011-02-20 |
| ES2362929T3 (es) | 2011-07-15 |
| US7538101B2 (en) | 2009-05-26 |
| ATE507222T1 (de) | 2011-05-15 |
| CN101316838A (zh) | 2008-12-03 |
| WO2007062997A1 (en) | 2007-06-07 |
| JP2009517431A (ja) | 2009-04-30 |
| EP1968967A1 (en) | 2008-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR049696A1 (es) | Derivados de indol | |
| AR059094A1 (es) | Derivados de ciclohexil - sulfonamida | |
| AR061486A1 (es) | Derivados de 2-pirazinacarboxamida | |
| AR060593A1 (es) | 5-amido-2-carboxiamida-indoles | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| AR040694A1 (es) | Derivados de benzodioxol como antagonistas de los receptores cb1 | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR054799A1 (es) | Derivados de oxindol | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| AR060525A1 (es) | Piridin [3,4-b] pirazinonas. composiciones farmaceuticas | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| AR060535A1 (es) | Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| AR051413A1 (es) | Piridinureas de antranilamida como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |